阿替利珠单抗联合贝伐珠单抗、化疗治疗晚期非小细胞肺癌的研究现状
Research status of atezolizumab combined with bevacizumab plus chemotherapy for the treatment of advanced non-small cell lung cancer
赖厚芸 1梁燕 1李凤 1周进 2陈燕 3王怡鑫3
作者信息
- 1. 电子科技大学医学院附属肿瘤医院·四川省肿瘤医院,药学部,四川成都 610041;电子科技大学医学院,四川成都 610054
- 2. 电子科技大学医学院附属肿瘤医院·四川省肿瘤医院,胸部肿瘤内科,四川成都 610041
- 3. 电子科技大学医学院附属肿瘤医院·四川省肿瘤医院,药学部,四川成都 610041
- 折叠
摘要
免疫治疗已经彻底改变了晚期非小细胞肺癌患者的治疗,然而,由于其单药的低响应率,很多患者并不能从治疗中获益.将免疫治疗联合抗血管生成药和化疗可能有助于解决这一问题,而阿替利珠单抗与贝伐珠单抗、卡铂和紫杉醇(ABCP)的方案已被批准作为晚期转移性非小细胞肺癌的一线治疗方法,具有巨大的应用潜力.本综述归纳了 ABCP方案的抗肿瘤作用机制,总结了其针对不同亚组、不同治疗顺序的临床应用现状,该方案的安全性、经济性,以及ABCP方案中替换药物选择的可能性和新药的研发,为ABCP方案在非小细胞肺癌患者中的个体化应用提供参考.
Abstract
Immunotherapy had completely changed the treatment for patients with advanced non-small cell lung cancer.However,due to its low response rate as a monotherapy,many patients had not been able to benefit from the treatment.The combination of immunotherapy with anti-angiogenic drugs and chemotherapy might have helped to address this issue,and the regimen of atezolizumab with bevacizumab,carboplatin,and paclitaxel(ABCP)had been approved as a first-line treatment for advanced metastatic non-small cell lung cancer,holding great potential for application.This review had summarized the antitumor mechanisms of the ABCP regimen,had concluded the current status of its clinical application for different subgroups and treatment sequences,the safety and cost-effectiveness of the regimen,as well as the possibilities for alternative drug choices within the ABCP regimen and the development of new drugs,providing a reference for the personalized application of the ABCP regimen in patients with non-small cell lung cancer.
关键词
抗血管生成药/非小细胞肺癌/免疫治疗/联合治疗Key words
anti-angiogenic drug/non-small cell lung cancer/immunotherapy/combination therapy引用本文复制引用
基金项目
中国药学会医院药学专业委员会科研专项基金资助项目(CPA-Z05-ZC-2022-002)
四川省个体化药物治疗重点实验室基金资助项目(2021YB03)
四川省肿瘤医院青年优秀基金资助项目(YB2023026)
出版年
2024
国家科技期刊平台
NSTL
万方数据